What question did this study set out to answer?

To determine if blocking HCN channels affects migraine caused by K ATP channel activation.

April 5, 2026Open Access

Migraine induced by vascular K ATP channel activation is independent of HCN channel activity: A randomised controlled trial with translational validation

Puntos clave

To determine if blocking HCN channels affects migraine caused by K ATP channel activation.
Randomised double-blind placebo-controlled crossover design
Adults with migraine without aura participated
Intravenous levcromakalim followed by oral ivabradine or placebo
Primary endpoint was incidence of levcromakalim-induced migraine
Preclinical validation used mouse models to assess effects on tactile sensitivity.
Ivabradine did not affect migraine incidence compared to placebo (22/27 in both cases)
No significant difference in headache intensity (P = 0.11)
Haemodynamic responses were consistent across both study days
Mice showed no alteration in tactile hypersensitivity with ivabradine across multiple doses.

Resumen

ObjectiveTo investigate whether blockade of hyperpolarisation-activated cyclic nucleotide-gated (HCN) channels modifies migraine induced by activation of vascular ATP-sensitive potassium (KATP) channels.MethodsWe conducted a single-centre, randomised, double-blind, placebo-controlled, two-way crossover study in adults with migraine without aura. On two separate days, participants received intravenous levcromakalim followed immediately by either oral ivabradine or placebo in a balanced order. The primary endpoint was the 12-h incidence of levcromakalim-induced migraine. Secondary endpoints included the area under the curve (AUC) for headache intensity and haemodynamic responses. Parallel preclinical experiments were performed in a validated mouse model using von Frey-based tactile sensitivity to assess whether ivabradine, given as pretreatment or as rescue medication, alters levcromakalim-induced hypersensitivity.ResultsTwenty seven of 31 individuals completed the human study and provided data for the final analysis. Ivabradine did not modify the incidence of levcromakalim-induced migraine (22 of 27 after ivabradine and 22 of 27 after placebo; P > 0.99) or the AUC for headache intensity (P = 0.11). Haemodynamic responses did not differ between study days. In mice, ivabradine at multiple doses neither prevented nor reversed tactile hypersensitivity induced by repeated levcromakalim administration.ConclusionsHCN channel blockade does not influence migraine or nociceptive behaviour provoked by vascular KATP channel activation. These convergent human and preclinical findings indicate that HCN channels are not essential for the downstream transformation of vascular KATP channel activation into migraine pain and support a model in which migraine initiation arises from signalling at the vessel-to-neuron interface.Trial registrationClinicalTrials.gov; NCT04853797; Registered: 16-03-2021. Preclinical experiments were not preregistered beyond the animal ethical license (2017-15-0201-01358) from the Danish Animal Experiments Inspectorate.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo